- Dose regimen, age, and BMI are associated with odds of complete remission after rituximab therapy in patients with pemphigus.
Why this matters
- Rituximab is a first-line treatment for pemphigus, but predictors of remission had not been identified.
- 70.5% of patients achieved complete remission off therapy (CROT).
- 48.2% of patients achieved CROT after the first cycle of rituximab.
- Patients who received higher rituximab dose (lymphoma dose [375 mg/m2 weekly for 4 weeks]) vs rheumatoid arthritis dose (1000-mg infusions 14 days apart) were more likely to achieve CROT (OR, 2.70; P=.04).
- Older age was associated with achieving CROT (OR, 4.95 [P=.01] for ages 45.0-54.9 years; OR, 3.69 [P<.047 for ages years or age compared with p=".01" trend>
- BMI ≥35 kg/m2 was associated with reduced odds of achieving CROT (OR, 0.14; P=.01).
- 112 patients with pemphigus who were treated with rituximab were included.
- Funding: Veterans Health Administration.
- Retrospective study design.
- Small patient sample size.